Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. More Details
+ 2 more risks
Adequate balance sheet and overvalued.
Share Price & News
How has Obalon Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OBLN's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: OBLN underperformed the US Medical Equipment industry which returned 25.5% over the past year.
Return vs Market: OBLN underperformed the US Market which returned 18.3% over the past year.
Price Volatility Vs. Market
How volatile is Obalon Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StThe Obalon Therapeutics (NASDAQ:OBLN) Share Price Is Down 98% So Some Shareholders Are Very Salty
9 months ago | Simply Wall StHere's Why Obalon Therapeutics (NASDAQ:OBLN) Must Use Its Cash Wisely
10 months ago | Simply Wall StCould Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?
Is Obalon Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OBLN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: OBLN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OBLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OBLN is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (4.1x).
How is Obalon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OBLN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OBLN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OBLN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OBLN's revenue is expected to decline over the next 3 years (-124.2% per year).
High Growth Revenue: OBLN's revenue is forecast to decline over the next 3 years (-124.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OBLN's Return on Equity is forecast to be high in 3 years time
How has Obalon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OBLN is currently unprofitable.
Growing Profit Margin: OBLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OBLN is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare OBLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBLN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).
Return on Equity
High ROE: OBLN has a negative Return on Equity (-251.71%), as it is currently unprofitable.
How is Obalon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: OBLN's short term assets ($10.8M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: OBLN's short term assets ($10.8M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: OBLN's debt to equity ratio (6%) is considered satisfactory.
Reducing Debt: OBLN's debt to equity ratio has reduced from 101.7% to 6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OBLN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OBLN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.6% each year
What is Obalon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OBLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OBLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OBLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OBLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OBLN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andy Rasdal (62 yo)
Mr. Andrew P. Rasdal, also known as Andy, is President and Chief Executive Officer at Obalon Therapeutics, Inc. since June 2020. Mr. Rasdal served as the Chairman of the Board at Obalon Therapeutics, Inc. ...
CEO Compensation Analysis
Compensation vs Market: Andy's total compensation ($USD526.00K) is about average for companies of similar size in the US market ($USD578.04K).
Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.
|CEO, President & Director||0.33yr||US$526.00k||1.01% |
|CFO & Secretary||1yr||no data||0.21% |
Experienced Management: OBLN's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
|CEO, President & Director||0.33yr||US$526.00k||1.01% |
|Independent Director||12.75yrs||US$117.50k||0.13% |
|Independent Director||4.58yrs||US$130.00k||0.036% |
|Independent Director||4.75yrs||US$132.50k||0.15% |
|Independent Chairperson of the Board||0.33yr||US$130.00k||0.25% |
|Independent Director||8.42yrs||US$115.00k||0% |
Experienced Board: OBLN's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.
Obalon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Obalon Therapeutics, Inc.
- Ticker: OBLN
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$7.419m
- Shares outstanding: 7.73m
- Website: https://www.obalon.com
Number of Employees
- Obalon Therapeutics, Inc.
- 5421 Avenida Encinas
- Suite F
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OBLN||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Oct 2016|
|24OA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 2016|
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon Syst ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 00:04|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.